Discover
GRACEcast Lung Cancer Video
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
Update: 2014-07-08
Share
Description
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Comments
In Channel



